Literature DB >> 11782376

Intestinal alkalization as a possible preventive mechanism in irinotecan (CPT-11)-induced diarrhea.

Tadashi Ikegami1, Linan Ha, Kazuhiko Arimori, Patricia Latham, Kunihiko Kobayashi, Susan Ceryak, Yasushi Matsuzaki, Bernard Bouscarel.   

Abstract

The therapeutic efficacy of irinotecan (CPT-11), a DNA topoisomerase inhibitor, is often limited by the induction of severe late-onset diarrhea. This prodrug and its active metabolite, 7-ethyl-10-hydroxy-camptothecin (SN-38), have a labile alpha-hydroxy-lactone ring that undergoes pH-dependent reversible hydrolysis. At physiological pH and higher, equilibrium favors the less toxic carboxylate form, whereas at acidic pH, the more potent lactone form is favored. We have reported previously that the initial uptake rate of CPT-11 and SN-38 by intestinal cells was significantly different between the respective lactone and carboxylate form. Results from the present study in HT-29 cells further demonstrate the correlation between the CPT-11/SN-38 initial uptake rate and the induced toxicity, cell cycle alteration, apoptosis, and colony-forming efficiency. The exposure of HT-29 cells to SN-38 for a limited period of time (<2 h) was sufficient to induce these events. Because the decreased initial uptake of SN-38 carboxylate resulted in a reduced cellular toxicity, we postulated that the CPT-11-induced diarrhea was preventable by influencing the equilibrium toward the carboxylate form and, thus, reducing its intestinal uptake. In the golden Syrian hamster model, p.o. sodium bicarbonate supplementation (5 mg/ml in drinking water) led to alkalization of the intestinal contents. In addition, this alkalization resulted in the reduction of the histopathological damage to the mucosa of the small and large intestine, as well as a 20% reduction of the intestinal SN-38 lactone concentration of animals receiving CPT-11 (20-50 mg/kg x 7 days). Taken together, these results from in vitro and in vivo studies support intestinal alkalization by sodium bicarbonate supplementation as a preventive mechanism against CPT-11-induced diarrhea. In addition, this provides a strong rationale for the usage of this measure as an adjunct to CPT-11 treatment.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11782376

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  13 in total

Review 1.  Prevention of irinotecan associated diarrhea by intestinal alkalization. A pilot study in gastrointestinal cancer patients.

Authors:  Vicente Valentí Moreno; Joan Brunet Vidal; Hermini Manzano Alemany; Antonia Salud Salvia; Montserrat Llobera Serentill; Inés Cabezas Montero; Sonia Servitja Tormo; Eugenia Sopena Bert; Josep Gumà Padró
Journal:  Clin Transl Oncol       Date:  2006-03       Impact factor: 3.405

2.  Rapid deconjugation of SN-38 glucuronide and adsorption of released free SN-38 by intestinal microorganisms in rat.

Authors:  Akira Takakura; Akinobu Kurita; Takashi Asahara; Masanori Yokoba; Michiko Yamamoto; Shinichiro Ryuge; Satoshi Igawa; Yukitoshi Yasuzawa; Jiichiro Sasaki; Hirosuke Kobayashi; Noriyuki Masuda
Journal:  Oncol Lett       Date:  2011-12-09       Impact factor: 2.967

3.  St. John's Wort modulates the toxicities and pharmacokinetics of CPT-11 (irinotecan) in rats.

Authors:  Zeping Hu; Xiaoxia Yang; Paul Chi-Liu Ho; Eli Chan; Sui Yung Chan; Congjian Xu; Xiaotian Li; Yi-Zhun Zhu; Wei Duan; Xiao Chen; Min Huang; Hongyuan Yang; Shufeng Zhou
Journal:  Pharm Res       Date:  2005-06-08       Impact factor: 4.200

Review 4.  Therapeutic targeting of CPT-11 induced diarrhea: a case for prophylaxis.

Authors:  Umang Swami; Sanjay Goel; Sridhar Mani
Journal:  Curr Drug Targets       Date:  2013-06       Impact factor: 3.465

5.  First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies.

Authors:  Glen J Weiss; Joseph Chao; Jeffrey D Neidhart; Ramesh K Ramanathan; Dawn Bassett; James A Neidhart; Chung Hang J Choi; Warren Chow; Vincent Chung; Stephen J Forman; Edward Garmey; Jungyeon Hwang; D Lynn Kalinoski; Marianna Koczywas; Jeffrey Longmate; Roger J Melton; Robert Morgan; Jamie Oliver; Joanna J Peterkin; John L Ryan; Thomas Schluep; Timothy W Synold; Przemyslaw Twardowski; Mark E Davis; Yun Yen
Journal:  Invest New Drugs       Date:  2013-02-09       Impact factor: 3.850

6.  Small cell carcinoma of the prostate treated with amrubicin.

Authors:  Manabu Katou; Norihito Soga; Takehisa Onishi; Kiminobu Arima; Yoshiki Sugimura
Journal:  Int J Clin Oncol       Date:  2008-05-08       Impact factor: 3.402

Review 7.  Camptothecin and podophyllotoxin derivatives: inhibitors of topoisomerase I and II - mechanisms of action, pharmacokinetics and toxicity profile.

Authors:  Jörg T Hartmann; Hans-Peter Lipp
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

Review 8.  Modifications of human carboxylesterase for improved prodrug activation.

Authors:  Jason M Hatfield; Monika Wierdl; Randy M Wadkins; Philip M Potter
Journal:  Expert Opin Drug Metab Toxicol       Date:  2008-09       Impact factor: 4.481

9.  Saccharic acid 1.4-lactone protects against CPT-11-induced mucosa damage in rats.

Authors:  Marina Fittkau; Wieland Voigt; Hans-Jürgen Holzhausen; Hans-Joachim Schmoll
Journal:  J Cancer Res Clin Oncol       Date:  2004-07       Impact factor: 4.553

10.  Phase I/II study of sequential therapy with irinotecan and S-1 for metastatic colorectal cancer.

Authors:  T Yoshioka; S Kato; M Gamoh; N Chiba; T Suzuki; N Sakayori; S Kato; H Shibata; H Shimodaira; K Otsuka; Y Kakudo; S Takahashi; C Ishioka
Journal:  Br J Cancer       Date:  2009-11-17       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.